TY - JOUR
T1 - Virology, epidemiology and control of SARS-CoV-2
T2 - A perspective
AU - Saeidi, Elnaz
AU - Ranjbar, Reza
AU - Zangoei-Fard, Soheil
AU - Guest, Paul C.
AU - Sahebkar, Amirhossein
PY - 2021/3
Y1 - 2021/3
N2 - SARS-CoV-2 is a human-infecting coronavirus, is the causative agent of COVID-19 disease. The World Health Organization declared this disease as a pandemic on 11 March 2020. The genome of SARS-CoV-2 is ~30kb in length which encodes sixteen nonstructural and four main structural proteins. The structural spike protein enables SARS-CoV-2 to bind to the host cell receptor angiotensin-converting enzyme 2 (ACE2), which leads to viral infection. COVID-19 is considered as a respiratory disease that affects just the lungs in most cases. Consequently, the principal approach to prevent this disease is supportive care. Efficient SARS-CoV-2 vaccines and altering treatments such as dexamethasone, tocilizumab and antibody cocktails have been developed in several countries. Due to their potential to increase drug bioavailability, a number of approaches in pharmaceutical nanotechnology are currently being tested against SARS-CoV-2. This includes nano-based products designed for detection, prevention and treatment of COVID-19. Such approaches may help to control this current pandemic and pave the way for prevention and treatment of future coronavirus outbreaks.
AB - SARS-CoV-2 is a human-infecting coronavirus, is the causative agent of COVID-19 disease. The World Health Organization declared this disease as a pandemic on 11 March 2020. The genome of SARS-CoV-2 is ~30kb in length which encodes sixteen nonstructural and four main structural proteins. The structural spike protein enables SARS-CoV-2 to bind to the host cell receptor angiotensin-converting enzyme 2 (ACE2), which leads to viral infection. COVID-19 is considered as a respiratory disease that affects just the lungs in most cases. Consequently, the principal approach to prevent this disease is supportive care. Efficient SARS-CoV-2 vaccines and altering treatments such as dexamethasone, tocilizumab and antibody cocktails have been developed in several countries. Due to their potential to increase drug bioavailability, a number of approaches in pharmaceutical nanotechnology are currently being tested against SARS-CoV-2. This includes nano-based products designed for detection, prevention and treatment of COVID-19. Such approaches may help to control this current pandemic and pave the way for prevention and treatment of future coronavirus outbreaks.
KW - Control
KW - Pandemic
KW - Respiratory disease
KW - SARS-CoV-2
KW - Viral infection
UR - http://www.scopus.com/inward/record.url?scp=85114911845&partnerID=8YFLogxK
U2 - 10.22034/nmrj.2021.02.001
DO - 10.22034/nmrj.2021.02.001
M3 - Review article
AN - SCOPUS:85114911845
SN - 2476-3489
VL - 6
SP - 96
EP - 104
JO - Nanomedicine Research Journal
JF - Nanomedicine Research Journal
IS - 2
ER -
